Advertisement
U.S. markets closed
Advertisement

Cellectar Biosciences, Inc. (CLRB)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Visitors trend2W10W9M
2.2400+0.0100 (+0.45%)
At close: 04:00PM EST
2.1900 -0.05 (-2.23%)
After hours: 05:24PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Performance Outlook
Previous Close2.2300
Open2.2300
Bid2.1800 x 1300
Ask2.4800 x 1200
Day's Range2.1800 - 2.2900
52 Week Range1.2500 - 3.1500
Volume183,029
Avg. Volume734,598
Market Cap22.273M
Beta (5Y Monthly)1.12
PE Ratio (TTM)N/A
EPS (TTM)-3.2600
Earnings DateNov 02, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.60
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CLRB

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Cellectar Biosciences, Inc.
    Weekly Stock ListBlack Friday. Cyber Monday. The retailers are out in force, with a massive marketing push to win dollars during this prime shopping time during the holidays. Just like retail, some stocks are seemingly at a big discount right now. Yes, we have our own Black Friday on Wall Street. But shop with care. We look for quality companies with solid books, proven track records, and strong management. This week, we used the Argus screening tool to create a list of companies that have clean balance sheets, high levels of profitability, and that we think are also undervalued and offer possible buying opportunities. We sorted the Argus stock universe for companies with a BUY rating, a market cap over $8 billion, and the highest financial strength ratings. Then we looked for those that are furthest away from their 52-week highs, and thus likely offering the deepest discounts. The resulting list is weighted towards Financial. That's not surprising based on the beating that the Financial sector took earlier this year after the collapse of Silicon Valley Bank. Here is our list of recommended Black Friday Stock Deals for November 2023.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • Simply Wall St.

    Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Situation

    Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

  • Insider Monkey

    Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q3 2023 Earnings Call Transcript

    Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q3 2023 Earnings Call Transcript November 2, 2023 Operator: Good morning, and welcome to Cellectar Biosciences Third Quarter 2023 Update Call. Today’s conference is being recorded. At this time, I would like to turn the conference over to Monique Kosse of LifeSci Advisors. Please go ahead. Monique Kosse: Thank you, operator, […]

  • GlobeNewswire

    Cellectar to Release Top-line Data from WM Pivotal Trial During the JP Morgan Healthcare Conference the Week of January 8, 2024

    Reports Preliminary Financial Results for Third Quarter 2023 and Provides a Corporate Update Conference Call scheduled for today at 8:30 am Eastern Time FLORHAM PARK, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced that top-line data from the pivotal trial in Waldenstrom’s macroglobulinemia (